New Disease-Modifying Therapies and New Challenges for MS
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The availability of the second-generation therapies for relapsing multiple sclerosis (MS), natalizumab and fingolimod, provides new treatment options for MS but also presents new challenges. Both natalizumab and fingolimod appear to be more effective than the interferon beta products and glatiramer acetate, but both have more safety problems than do the first-generation therapies. Treatment with natalizumab is associated with a significant risk of patients developing progressive multifocal leukoencephalopathy (PML), which the JC virus causes. We now are able to risk stratify MS patients into high- and low-risk groups for developing PML on the basis of the presence or absence of antibodies to the JC virus, history of prior use of immunosuppressants, and duration of therapy with natalizumab. Fingolimod appears to be associated with a risk of asystole and sudden death. It may also increase the risk of serious herpes infections and paradoxical activation of MS. More information is needed about these serious side effects from fingolimod to allow us to use it safely in patients.
- Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910. CrossRef
- Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23. CrossRef
- Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18:1–11. CrossRef
- Biogen Idec communication: PML incidence in patients receiving TYSABRI® (natalizumab); 2012.
- Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18:143–52. CrossRef
- Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295–303. CrossRef
- Product information: TYSABRI(R) intravenous injection, natalizumab intravenous injection. Elan Pharmaceuticals, Inc. (per manufacturer), South San Francisco, CA; 2012.
- Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012;78:436–7. CrossRef
- Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742–50. CrossRef
- Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91–101. CrossRef
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. CrossRef
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15. CrossRef
- U.S. Food and Drug Administration. FDA Drug Safety Communication. Safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). 2011 12/20/2011. Available from http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm.
- European Medicines Agency: European Medicines Agency starts review of Gilenya (fingolimod). Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/01/news_detail_001425.jsp&mid=WC0b01ac058004d5c1. Accessed May 2012.
- Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. Mult Scler. 2011;17:1387–9. CrossRef
- Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84–105. CrossRef
- Product Information: GILENYA(TM) oral capsules, fingolimod oral capsules. Novartis Pharmaceuticals Corporation (Per Manufacturer), East Hanover, NJ, 2012.
- U.S. Food and Drug Administration. Gilenya (fingolimod): drug safety communication. safety review of a reported death after the first dose. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm284355.htm. Accessed May 2012.
- Uccelli A, Ginocchio F, Mancardi GL, et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology. 2011;76:1023–4. CrossRef
- Nealon N. Severe multiple sclerosis relapse on fingolimod. 5th Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands; 2011.
- Castrop F, Kowarik MC, Albrecht H, et al. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology. 2012;78:928–30. CrossRef
- New Disease-Modifying Therapies and New Challenges for MS
Current Neurology and Neuroscience Reports
Volume 12, Issue 5 , pp 489-491
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Multiple sclerosis
- Progressive multifocal leukoencephalopathy
- Anti-JCV antibody
- Industry Sectors